Effect of gene polymorphism on the efficacy of direct oral anticoagulant therapy in patients with venous thromboembolism

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019890

Enrollment

Unknown

Registered

2018-12-07

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism

Interventions

Group 1:Dabigatran

Group 2:Rivaroxaban

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Voluntary signature of informed consent; aged 18 and 75 years old; diagnosis of VTE patients.

Exclusion criteria

Exclusion criteria: Patients with a history of ischemic cardiomyopathy, including myocardial infarction, symptomatic coronary artery disease within 6 months before admission to the clinical trial, cancer patients with VTE, emotional instability or intellectual inability to understand the objectives, nature of the study and the consequences of participating in the study, or any other possible unacceptable safety that the researchers consider unacceptable Whole risk situation

Design outcomes

Primary

Measure	Time frame
Gene polymorphism;	—

Secondary

Measure	Time frame
Peak Drug Concentration of Dapigatron Ester;Tough Drug Concentration of Dapigatron Ester;Peak drug concentration of Rivaroxaban;Tough drug concentration of Rivaroxaban;	—

Countries

China

Contacts

Public ContactRong Jiang

Shanghai Pulmonary Hospital

listening39@163.com+86 13795493921

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026